Groslay

Researchers are collecting a set of ultrasound images and video clips from patients who undergo routine lower limb ultrasound scans due to suspected deep vein thrombosis (DVT). This effort aims to create a labeled data set that will be used to train artificial intelligence (AI) models for automated detection of DVT. The importance of this research lies in improving early diagnosis of DVT, a condition that can lead to serious complications such as pulmonary embolism, which is a leading cause of preventable death in hospitals. The study gathers ultrasound images from patients referred for scans based on a conventional diagnostic DVT algorithm or suspicion of DVT. The collected data includes not only images but also metadata like patient demographics, referral notes, known medical conditions at the time of the scan, anonymized operator IDs, and details about the ultrasound equipment used. The data set will include various types of scans, such as those negative for DVT, positive for DVT, positive for other diagnoses, and scans of insufficient quality, all anonymized according to regulations. Participants will undergo routine ultrasound scans, and the data collected during these scans will be used solely for research purposes. The study does not involve any interventions. Researchers will evaluate the ultrasound data collected on the first day. The anonymized data set will be made publicly available through the European Open Science Cloud portal to support further research and AI model training. The participation involves consenting adults who are undergoing ultrasound scans due to suspected DVT.

Researchers are evaluating the real-life effectiveness, safety, and usage patterns of Octapharma's factor VIII (FVIII) concentrates Nuwiq, Octanate, and Wilate in patients with severe haemophilia A who have either never been treated or have had minimal previous treatment. This study focuses on previously untreated patients (PUPs), often young children, and minimally treated patients (MTPs), to better understand treatment outcomes and inhibitor development in routine clinical practice. Because haemophilia A is rare and treatment practices vary, especially for PUPs, collecting real-world data is important to improve treatment guidelines and benefit-risk assessments. The study observes patients prescribed Octapharma's FVIII concentrates without changing their treatment, capturing how these products are used in everyday healthcare settings. There are no experimental interventions as this is a non-interventional study. The study includes patients starting or continuing treatment with these FVIII concentrates, monitoring their usage, dosing, and frequency as determined by their healthcare providers. Participants are monitored for effectiveness by tracking the annual rate of breakthrough bleeding episodes and safety by recording adverse drug reactions over 100 exposure days. Data on inhibitor development is also collected. Patients of all ages and genders with severe haemophilia A are eligible if they meet treatment history criteria. Informed consent is obtained before data collection. The study gathers information from routine clinical visits and treatment records without additional procedures or interventions.